Cytopathology Test Platform

Strategic relationship with renowned pathology leader – Strata Dx
- Board certified cytopathologists accessible for 24/7 consultation
- World class turnaround time averaging 2 days

APTIMA® HPV E6/E7 mRNA High Risk Screening

Greater detection of disease, less false positives than DNA genotyping
- Some HPV DNA tests may provide false-negative results in over 10% of most severe cervical disease cases
- APTIMA HPV has shown 24% fewer false-positive test results compared to hybrid capture

APTIMA HPV 16 18/45 Genotyping

Identifies the presence of the three genotypes associated with a vast majority of cervical cancers
- Only FDA approved test that includes genotyping for type 45, the high-risk genotype most prone to express oncogenic mRNA
- Types 16, 18, and 45 are associated with about 80% of all invasive cervical cancers, 75% of all squamous carcinomas, and 94% of all adeno carcinomas

APTIMA Combo 2 Chlamydia trachomatis/Neisseria Gonorrheae (CT/GC)

Accurate identification of two of the most common sexually transmitted diseases (STD’s) using the most versatile FDA approved collection options
- CDC guidelines recommend screening sexually active females, women with high risk factors and pregnant women be screened for CT/GC annually or as applicable
- Confident CT results due to confirmatory CT testing following CDC recommendations
- ThinPrep liquid Pap, urine, male and female swabs are all FDA approved collection options
**APTIMA Trichomonas**

Unparalleled detection performance and collection flexibility for the most common curable STD

- Curable STD that can cause vaginitis, urethritis, and cervicitis with potential complications that include adverse birth outcomes and pelvic inflammatory disease, complicated by asymptomatic rate of 10-50%[^7][^8]
- Only FDA approved nucleic acid amplification test from a multitude of collection devices including: female urine, ThinPrep liquid Pap specimens, clinician collected vaginal and endocervical swabs[^8]

**illumigene® Group B Streptococcus (GBS)**

Increased detection and sensitivity versus traditional culture testing

- ACOG recommends that all pregnant women routinely be screened for GBS at 35-37 weeks
- Broth enrichment and illumigene® GBS increases detection of positives by up to 29% over traditional culture[^9][^10]
- Additional sensitivity testing is available for penicillin allergic patients

**HIV Ag/Ab Combo Screening with HIV Multispot® confirmation**

Greater accuracy and reduced turnaround time

- Includes p24 antigen testing, allowing for detection 20 days earlier than antibody testing
- Demonstrates greater capability of detecting acute HIV infection versus previous methods
- Complies with New York State (NYS) interim guidelines for HIV diagnosis released in May 2013

---

[^2]: APTIMA HPV Assay package insert #502170 Rev A 2011
[^10]: illumigene® GBS package insert, May 2012.